KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Common Equity (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Common Equity for 8 consecutive years, with -$302.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 22.32% year-over-year to -$302.0 million, compared with a TTM value of -$302.0 million through Dec 2025, up 22.32%, and an annual FY2025 reading of -$302.0 million, up 22.32% over the prior year.
  • Common Equity was -$302.0 million for Q4 2025 at Esperion Therapeutics, up from -$451.4 million in the prior quarter.
  • Across five years, Common Equity topped out at -$196.9 million in Q4 2021 and bottomed at -$455.0 million in Q4 2023.
  • Average Common Equity over 5 years is -$343.5 million, with a median of -$336.9 million recorded in 2023.
  • The sharpest move saw Common Equity crashed 4148.05% in 2021, then grew 22.32% in 2025.
  • Year by year, Common Equity stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then plummeted by 40.53% to -$455.0 million in 2023, then grew by 14.57% to -$388.7 million in 2024, then rose by 22.32% to -$302.0 million in 2025.
  • Business Quant data shows Common Equity for ESPR at -$302.0 million in Q4 2025, -$451.4 million in Q3 2025, and -$433.5 million in Q2 2025.